Celldex Therapeutics $CLDX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING1
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| barzolvolimab NCT06366750 |
P2 | Active, not recruiting | Prurigo Nodularis | 140 | 2026-03-17 (+2 mo) |
| Barzolvolimab NCT06727552 |
P2 | Active, not recruiting | Atopic Dermatitis | 131 | 2026-05-06 (-5 mo) |
| EMBARQ-CSU2 NCT06455202 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria | 976 | 2026-08-04 (+10 mo) |
| EMBARQ-CSU1 NCT06445023 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria | 963 | 2026-08-12 (-2 mo) |
| Barzolvolimab NCT07266402 |
P3 | Recruiting | Chronic Inducible Urticaria; Cold Urticaria | 240 | 2028-06 |
| barzolvolimab NCT07256392 |
P3 | Enrolling by invitation | Chronic Spontaneous Urticaria | 1370 | 2028-09 |